Kosta Shatrov
Biographic Data
| ID | 9570576 |
|---|---|
| NAME | Kosta Shatrov |
| GIVEN NAMES | Kosta |
| FAMILY NAME | Shatrov |
| SIGNATURE | SHATROV K |
| AFFILIATIONS | University of Bern |
| ORCID | 0000-0002-6421-6754 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Why the US spends more treating high-need high-cost patients
One of the most pressing challenges facing most health care systems is rising costs. As the population ages and the demand for health care services grows, there is a growing need to understand the drivers of these costs across systems. This paper attempts to address this gap by examining utilization and spending of the course of a year for two specific high-need high-cost patient types: a frail older person with a hip fracture and an older person…
How to pay primary care physicians for Sars-CoV-2 vaccinations
Vaccinations are crucial to fighting SARS-CoV-2, and high coverage rates can in most countries probably only be achieved with the involvement of primary care physicians (PCPs). We aimed to explore how SARS-CoV-2 vaccination payment schemes in 43 countries differ with regard to the (i) type of payment scheme, (ii) amount paid, (iii) degree of bundling, and (iv) use of pay-for-performance elements. We collected information on payments and health sy…
After the four-year transition period
Regulatory and HTA early dialogues in medical devices
INTRODUCTION: Specific guidance and examples for health technology assessment (HTA) of medical devices are scarce in medical device development. A more intense dialogue of competent authorities, HTA agencies, and manufactures may improve evidence base on clinical and cost-effectiveness. Especially as the new Medical Device Regulation requires more clinical evidence. METHODS: We explore the perceptions of manufacturers, competent authorities, and …
No prominent works on this page.
Regulatory and HTA early dialogues in medical devices
INTRODUCTION: Specific guidance and examples for health technology assessment (HTA) of medical devices are scarce in medical device development. A more intense dialogue of competent authorities, HTA agencies, and manufactures may improve evidence base on clinical and cost-effectiveness. Especially as the new Medical Device Regulation requires more clinical evidence. METHODS: We explore the perceptions of manufacturers, competent authorities, and …
How to pay primary care physicians for Sars-CoV-2 vaccinations
Vaccinations are crucial to fighting SARS-CoV-2, and high coverage rates can in most countries probably only be achieved with the involvement of primary care physicians (PCPs). We aimed to explore how SARS-CoV-2 vaccination payment schemes in 43 countries differ with regard to the (i) type of payment scheme, (ii) amount paid, (iii) degree of bundling, and (iv) use of pay-for-performance elements. We collected information on payments and health sy…
After the four-year transition period
Why the US spends more treating high-need high-cost patients
One of the most pressing challenges facing most health care systems is rising costs. As the population ages and the demand for health care services grows, there is a growing need to understand the drivers of these costs across systems. This paper attempts to address this gap by examining utilization and spending of the course of a year for two specific high-need high-cost patient types: a frail older person with a hip fracture and an older person…
Business (4 works) · Economics (4 works) · Health care (4 works) · Health Systems, Economic Evaluations, Quality of Life (3 works) · Medicine (3 works) · Biomedical Ethics and Regulation (2 works) · Economic growth (2 works) · Family medicine (2 works) · Healthcare Policy and Management (2 works) · Law (2 works)